|1.||Kaufels, Nicola: 2 articles (04/2007 - 04/2004)|
|2.||Hamm, Bernd: 2 articles (04/2007 - 04/2004)|
|3.||Taupitz, Matthias: 2 articles (04/2007 - 04/2004)|
|4.||Laule, Michael: 2 articles (04/2007 - 04/2004)|
|5.||Schnorr, Jörg: 2 articles (04/2007 - 04/2004)|
|6.||Dewey, Marc: 2 articles (04/2007 - 04/2004)|
|7.||Choi, Byung Ihn: 1 article (09/2015)|
|8.||Han, Joon Koo: 1 article (09/2015)|
|9.||Kim, Young Il: 1 article (09/2015)|
|10.||Park, Hee Sun: 1 article (09/2015)|
09/01/2015 - "To evaluate the utility of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using macromolecular contrast agent (P792) for assessment of vascular disrupting drug effect in rabbit VX2 liver tumor models. "
09/01/2015 - "Dynamic Contrast-Enhanced MRI Using a Macromolecular MR Contrast Agent (P792): Evaluation of Antivascular Drug Effect in a Rabbit VX2 Liver Tumor Model."
08/15/2008 - "In the BN472 tumor model, early reduction of permeability, as detected by K(trans) quantification using the dynamic contrast-enhanced magnetic resonance imaging contrasting agent P792 (Vistarem), was found to be a predictive marker for late-stage antitumor activity by NVP-BEZ235."
10/01/2003 - "Using a macromolecular contrast agent (P792), a fast MR imaging protocol and a compartmental data analysis, we were able to demonstrate a significant simultaneous reduction in tumor vascular permeability, tumor vascular volume and tumor blood flow (43%, 30% and 42%, respectively) following ZD4190 treatment (100 mg/kg orally, 24 h and 2 h prior to imaging). "
04/01/2007 - "An optimized MR protocol using the blood pool contrast agent P792 (0.026 mmol/kg, twice the clinical dose, Guerbet, France) was investigated to evaluate nonreperfused myocardial infarction in an animal model. "
04/01/2004 - "If blood pool contrast media like P792 (Vistarem, Guerbet, France), in addition to improving coronary MR angiography, can be shown to also produce delayed enhancement in myocardial infarction they could improve the prerequisites for a comprehensive cardiac MR examination. "
|4.||Colorectal Neoplasms (Colorectal Cancer)